PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2010; 31(02): 58-61
DOI: 10.4103/0971-5851.71657
case report

Pseudomyxoma peritonei: An uncommon tumor

Surabhi Gupta
Department of Radiotherapy, S.N. Medical College, Agra
,
Garima Singh
Department of Radiotherapy, S.N. Medical College, Agra
,
Anurag Gupta
Department of Pathology, S.N. Medical College, Agra
,
Hari Singh
Department of Pathology; Consultant Radiologist, S.N. Medical College, Agra
,
A K Arya
Department of Radiotherapy, S.N. Medical College, Agra
,
Deepak Shrotriya
Department of Radiotherapy, S.N. Medical College, Agra
,
Anuj Kumar
Department of Radiotherapy, S.N. Medical College, Agra
› Institutsangaben
Source of Support Nil.
› Weitere Informationen
Auch verfügbar auf
 als PDF herunterladen Lizenzen und Reprints

Abstract

Pseudomyxoma peritonei is a poorly understood and uncommon tumor that is known for its production of mucin in the abdominal cavity and mucinous implants, diffusely involving the peritoneal surfaces. A 60-year-old female presented to us with post-op complaints of diffuse abdominal pain and distension. On work-up, she was diagnosed as a case of Pseudomyxoma peritonei (with residual disease). She received chemotherapy in the form of oral capecitabine for residual disease. She was totally asymptomatic till the last follow-up. This case is being reported on account of its rarity and to emphasize a simple alternative treatment option as compared to the standard one.

Keywords

Oral capecitabine - Pseudomyxoma peritonei


Publikationsverlauf

Artikel online veröffentlicht:
19. November 2021

© 2010. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995;19:1390-408.
  • 2 Van Ruth S, Acherman YI, van de Vijver MJ, Hart AA, Verwaal VJ, Zoetmulder FA. Pseudomyxoma peritonei: A review of 62 cases. Eur J Surg Oncol 2003;29:682-8.
  • 3 Van Ruth S, Hart AA, Bonfrer JM, Verwaal VJ, Zoetmulder FA.Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002;9:961-7.
  • 4 Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001;27:239-43.
  • 5 Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001;88:458-63.
  • 6 Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): A strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004;11:393-8.
  • 7 Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85-91.
  • 8 Levitz JS, Sugarbaker PH, Lichtman SM, Brun EA. Unusual abdominal tumors, case 1. Pseudomyxoma peritonei: Response to capecitabine. J Clin Oncol 2004;22:1518-20.
  • 9 Van Cutsem E, Peeters M. Developments in fluoropyrimidine therapy for gastrointestinal cancer. Curr Opin Oncol 1999;11:312-7.